乳腺癌新辅助化疗后病理完全缓解的影响因素:预测列线图的开发与验证
单中心回顾性研究纳入II-III期乳腺癌患者,开发队列359例、验证队列351例,基于临床病理变量及NAC前后乳腺X线和MRI变量构建预测pCR的列线图。列线图在独立验证队列中显示出良好的区分度(AUC 0.90;95%CI 0.86, 0.94)和校准能力(校准斜率0.91;95%CI 0.69, 1.13)。
要点
- 激素受体阴性、高Ki-67指数及NAC后MRI显示肿瘤小、病灶-背景实质信号增强比低、瘤床无强化与pCR独立相关。
- 列线图整合临床病理与MRI变量预测pCR,验证队列AUC 0.90(95%CI 0.86, 0.94)。
- NAC后MRI瘤床无强化者pCR odds更高(OR 3.8;95%CI 1.4, 10.5;P = .009)。
关键影像表现/征象
- NAC后MRI显示肿瘤体积小(OR 0.6;95%CI 0.4, 0.9;P = .03)与pCR独立相关。
- NAC后MRI病灶-背景实质信号增强比低(OR 0.2;95%CI 0.1, 0.6;P = .004)与pCR独立相关。
- NAC后MRI瘤床无强化(OR 3.8;95%CI 1.4, 10.5;P = .009)与pCR独立相关。
诊断标准与关键数值
- 激素受体阴性(OR 3.1;95%CI 1.4, 7.1;P = .006)与pCR独立相关。
- 高Ki-67指数(OR 1.05;95%CI 1.03, 1.07;P < .001)与pCR独立相关。
- 列线图在独立验证队列中AUC为0.90(95%CI 0.86, 0.94),校准斜率为0.91(95%CI 0.69, 1.13)。
临床应用与阅片要点
- 列线图纳入激素受体状态、Ki-67指数及NAC前后MRI变量(肿瘤大小、病灶-背景实质信号增强比、瘤床强化情况)用于预测pCR。
- NAC后MRI评估需关注肿瘤大小、病灶-背景实质信号增强比及瘤床有无强化,这些变量被纳入预测模型。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background There is an increasing need to develop a more accurate prediction model for pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer. Purpose To develop a nomogram based on MRI and clinical-pathologic variables to predict pCR. Materials and Methods In this single-center retrospective study, consecutive women with stage II-III breast cancer who underwent NAC followed by surgery between January 2011 and December 2017 were considered for inclusion. The women were divided into a development cohort between January 2011 and September 2015 and a validation cohort between October 2015 and December 2017. Clinical-pathologic data were collected, and mammograms and MRI scans obtained before and after NAC were analyzed. Logistic regression analyses were performed to identify independent variables associated with pCR in the development cohort from which the nomogram was created. Nomogram performance was assessed with the area under the receiver operating characteristic curve (AUC) and calibration slope. Results A total of 359 women (mean age, 49 years ± 10 [standard deviation]) were in the development cohort and 351 (49 years ± 10) in the validation cohort. Hormone receptor negativity (odds ratio [OR], 3.1; 95% CI: 1.4, 7.1; P = .006), high Ki-67 index (OR, 1.05; 95% CI: 1.03, 1.07; P < .001), and post-NAC MRI variables, including small tumor size (OR, 0.6; 95% CI: 0.4, 0.9; P = .03), low lesion-to-background parenchymal signal enhancement ratio (OR, 0.2; 95% CI: 0.1, 0.6; P = .004), and absence of enhancement in the tumor bed (OR, 3.8; 95% CI: 1.4, 10.5; P = .009) were independently associated with pCR. The nomogram incorporating these variables showed good discrimination (AUC, 0.90; 95% CI: 0.86, 0.94) and calibration abilities (calibration slope, 0.91; 95% CI: 0.69, 1.13) in the independent validation cohort. Conclusion A nomogram incorporating hormone receptor status, Ki-67 index, and MRI variables showed good discrimination and calibration abilities in predicting pathologic complete response. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Imbriaco and Ponsiglione in this issue.
引用
- Kim SY, Cho N, Choi Y, et al. Factors Affecting Pathologic Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer: Development and Validation of a Predictive Nomogram. Radiology. 2021. PMID: 33754824. doi:10.1148/radiol.2021203871
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。